Founded in 2001 by Amy Tseng, President and CEO, and Dr. Scheffer Tseng, Chairman and Chief Scientific Officer, TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care. The Company has pioneered stem cell research using human amniotic membrane to treat corneal surface conditions and developed Amniograft™, the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation. The National Institute of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since inception, 130,000 human implants have been conducted using the Company’s patented Crotek™ process and 300 peer-reviewed scientific publications have been produced supporting the technology platform.
Amniox® Medical Announces Study Confirming Superiority of Proprietary Cryopreservation Technology for Processing Umbilical Cord & Amniotic Membrane Tissue
Peer-reviewed study concludes cryopreservation preserves biological tissue properties while dehydration drastically alters the structural and biological integrity of tissue.
Greater Miami Chamber of Commerce recognizes local company for its exemplary business performance and contribution to the community.
Subsidiary of TissueTech Bio-Tissue, Inc., an ophthalmic biologic therapeutics company, has announced the introduction of two next-generation PROKERA Biologic Corneal Bandage devices.
TissueTech, Inc., the industry leader in regenerative tissue engineering, announced the completion of a $10 million round of growth equity financing from Ballast Point Ventures and River Cities Capital Funds.